Three notes:
1. Results demonstrated that Linzess, developed by Ironwood Pharmaceuticals, was associated with a significant improvement in abdominal score compared to placebo in adult IBS-C patients.
2. The abdominal score includes symptoms that IBS-C patients identify as bothersome and important to treat, such as bloating, pain and discomfort.
3. Study results may “help physicians and patients have a more comprehensive discussion about these bothersome symptoms and ways to manage them,” Lin Chang, MD, vice chief of digestive diseases at the University of California Los Angeles, said in a June 16 news release.
Click here for more details on the clinical trial.
